What is Ionpath?
Ionpath, Inc. is a trailblazer in high-definition spatial proteomics, fundamentally transforming tissue imaging and analysis to accelerate breakthroughs in human health. The company's proprietary MIBI (multiplexed ion beam imaging) platform surpasses the limitations of conventional immunohistochemistry (IHC), offering unparalleled, quantitative single-cell analysis within the tissue microenvironment. This advanced technology empowers translational and clinical researchers across leading pharmaceutical, biotechnology, and research organizations, providing critical insights for immuno-oncology, immunology, neuroscience, and infectious disease research.
How much funding has Ionpath raised?
Ionpath has raised a total of $20M across 3 funding rounds:
Debt
$1M
Series B
$18M
Debt
$1M
Debt (2020): $1M with participation from PPP
Series B (2020): $18M led by Genoa Ventures, Trancos IONpath Investors, Vertical Venture Partners Growth Fund, Bruker Corporation, Samsara BioCapital, ND Capital, Norwich Ventures, and Paladin Partners Investments
Debt (2021): $1M supported by PPP
Key Investors in Ionpath
Genoa Ventures
Genoa Ventures is an investment firm that likely focuses on technology and venture capital opportunities, potentially including life sciences given the context of Ionpath's work.
Samsara BioCapital
Samsara BioCapital is a venture capital firm specializing in the life sciences sector, with a focus on companies developing innovative therapeutics and technologies.
Norwich Ventures
Norwich Ventures is a specialized venture capital firm established in 2004, focusing on early-stage medtech investments. The firm seeks to support entrepreneurs developing innovative technologies that address significant unmet medical needs.
What's next for Ionpath?
With the recent infusion of $1M as part of a major strategic investment, Ionpath is poised for accelerated growth and further innovation. This substantial backing, contributing to its $20M in overall financing, will likely fuel the expansion of its MIBI platform's reach into new research areas and clinical applications. The company's focus on providing deep, quantitative insights into tissue biology positions it as a key enabler for precision medicine and drug development.
See full Ionpath company page
